7 Hills Pharma
- Company typePrivate
- Founded2018
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
7 Hills Pharma firmographics
Firmographics- Name
- 7 Hills Pharma
- Legal name
- 7 Hills Pharma Inc.
- Website
- https://7hillspharma.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
7 Hills Pharma industry classification
Industry- Product category
- Immuno-oncology biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)
Keywords
Where 7 Hills Pharma is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
7 Hills Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Licensing and Partnership Revenue: 7 Hills Pharma generates revenue through licensing its integrin activator technology to larger pharmaceutical companies for clinical development and commercialization. The company seeks partnerships with vaccine and immuno-oncology developers.
- Nondilutive Grant Funding: The company has received over $34 million in nondilutive grant funding from NIH institutions (NIAID, NHLBI, NCI) and CPRIT to fund clinical development without diluting equity.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
7 Hills Pharma product offering
Product offeringCore offering
7 Hills Pharma is a clinical-stage drug development company advancing first-in-class oral small molecule integrin agonists (Alintegimod/7HP349 and 7HP935) designed to enhance immune responses for cancer immunotherapy and hematopoietic stem cell transplantation. The company's pipeline targets anti-PD-1-resistant solid tumors, acute leukemias, genetic bone marrow disorders, and infectious disease vaccines including COVID-19, influenza, and Chagas disease.
Product overview
7 Hills Pharma is a clinical-stage drug development company advancing two first-in-class integrin-targeted small molecule agonists: Alintegimod (formerly 7HP349) for overcoming immunotherapy resistance in solid tumors and hematological malignancies, and 7HP935 for improving cell and gene therapy outcomes in hematopoietic stem cell transplantation. The company's proprietary platform leverages allosteric integrin activation to enhance antigen-specific immune responses when combined with checkpoint inhibitors, vaccines, or cell-based therapies. Additionally, the company developed THI0019, an early VLA-4 integrin agonist for stem cell therapy applications.
Differentiator
Problem solved
Functional benefit
Brands
- Alintegimod: First-in-class dual LFA-1 and VLA-4 agonist designed to overcome anti-PD-1 resistance in solid tumors when used with immune checkpoint inhibitors. Formerly known as 7HP349.
- 7HP935
Products and services
- Alintegimod (formerly 7HP349) First-in-class, dual LFA-1 and VLA-4 agonist oral small molecule designed to be used in combination with immune checkpoint inhibitors to safely overcome resistance to anti-PD-1 drugs in solid tumors. Currently enrolling patients in a Phase 1b/2a clinical trial for aPD-1-resistant solid tumors, with FDA Fast Track and Orphan Drug designations for advanced melanoma.
- 7HP935 First-in-class small molecule gene therapy enhancer designed to improve the effectiveness of CD34+ cell-based therapies for the treatment of acute leukemias and genetic disorders of the bone marrow. Currently undergoing IND-enabling studies to support a Phase I trial in hematopoietic stem cell transplantation, with focus on reducing graft failure and addressing racial disparities in donor matching.
- THI0019 First small molecule agonist of VLA-4 integrin (α4β1) designed to enhance progenitor cell adhesion and improve stem cell therapy outcomes. Generated via structural modifications to a previously identified α4β1 antagonist.
Quantifiable outcome
- Phase I trial completed with no treatment-related adverse events at exposures exceeding 9x therapeutic levels
- +2 more outcomes
Companies that use 7 Hills Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
7 Hills Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
7 Hills Pharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- MD Anderson Cancer CentercoreCollaborative research with Yared Hailemichael, Ph.D. and team leading to publication in Journal of Clinical Investigation demonstrating how 7HP349 converts cold tumors to hot, T cell-enriched tumors.
- Texas Heart InstitutecoreCo-inventors and original developers of the integrin activator technology. 7 Hills partnered with THI in 2014 to commercially develop the technology. THI scientists Peter Vanderslice, Ronald J. Biediger, and Darren G. Woodside discovered the compound family using rational design based on integrin biology and structure.
- Johnson & Johnson Innovation – JLABS (Blue Knight)coreSelected participant in Blue Knight collaboration with BARDA to help battle COVID-19 pandemic. One of seven companies in US, Canada, and Europe in the program.
- Catalent Pharma SolutionsminorManufacturing partnership for scalable production of 7HP349. Catalent's softgel site in St. Petersburg, Florida has capacity for up to 8 billion capsules annually.
- Eurofins AdvinusminorManufacturing partnership for drug development and production scale-up.
- Lipoid LLCminorManufacturing partnership for formulation and production of 7HP349.
- University of Texas Medical Branch (UTMB)coreCollaboration with Dr. Nisha Garg's laboratory for Chagas disease vaccine development. Joint research published in Nature Partner Journal Vaccines demonstrating 7HP349 as vaccine adjuvant.
- UTHealth (University of Texas Health Science Center at Houston)minorCollaboration with Professor Jeffrey Actor to develop 7HP349 as oral immunostimulant for COVID-19 and influenza vaccinations.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
7 Hills Pharma competitors and assessment
Company assessmentDirect peers
- Werewolf Therapeutics: Clinical-stage immuno-oncology company developing first-in-class conditionally activated therapeutics. Comparable as a small, venture-backed IO biotech with a novel mechanism platform targeting solid tumor resistance and a similar development stage.
- Corvus Pharmaceuticals: Clinical-stage biopharma developing immune modulator therapies for cancer, including adenosine and ITK pathways. Comparable in target indication (PD-1-resistant solid tumors) and small-cap clinical-stage profile.
- Surface Oncology: Clinical-stage immuno-oncology company focused on next-generation antibodies targeting the tumor microenvironment. Comparable as a small-cap IO biotech pursuing combinations with checkpoint inhibitors.
- Jounce Therapeutics: Clinical-stage immuno-oncology company developing novel immunotherapies including PD-1 resistance approaches. Comparable clinical-stage IO profile and solid tumor focus targeting checkpoint resistance.
- Apexigen: Clinical-stage immuno-oncology company developing CD40 agonist antibodies and other innate immune activators. Comparable as a small clinical-stage biotech using immune activation to overcome checkpoint resistance.
- Compugen: Clinical-stage immuno-oncology company leveraging computational discovery to identify novel immune targets, including combos with checkpoint inhibitors. Comparable clinical-stage IO platform model.
- Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers. Comparable clinical-stage, small-cap oncology profile with pipeline diversification.
Broad incumbents
- Bristol-Myers Squibb: Global pharmaceutical leader with deep immuno-oncology franchise including Opdivo and Yervoy. Sets the competitive bar in PD-1-resistant melanoma and is a logical potential licensing or acquisition partner for 7 Hills Pharma.
- Merck & Co. Global pharma leader with Keytruda checkpoint inhibitor franchise, actively pursuing combination strategies in PD-1-resistant tumors. Represents both a competitive threat and a potential acquirer for integrin-based combination agents.
Emerging players
- Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR therapies for solid tumors. Comparable clinical-stage oncology profile with cell therapy focus overlapping 7 Hills' 7HP935 program in hematologic malignancies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
7 Hills Pharma social profiles
Digital presence7 Hills Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
7 Hills Pharma leadership team
Management profileNumber of profiles
Profiles8 records
7 Hills Pharma funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
7 Hills Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 7 Hills Pharma
What does 7 Hills Pharma do?
7 Hills Pharma is a clinical-stage drug development company advancing first-in-class oral small molecule integrin agonists (Alintegimod/7HP349 and 7HP935) designed to enhance immune responses for cancer immunotherapy and hematopoietic stem cell transplantation. The company's pipeline targets anti-PD-1-resistant solid tumors, acute leukemias, genetic bone marrow disorders, and infectious disease vaccines including COVID-19, influenza, and Chagas disease.
Is 7 Hills Pharma a public or private company?
7 Hills Pharma is a private company. It is classified as unknown and is currently operating.
When was 7 Hills Pharma founded?
7 Hills Pharma was founded in 2018. It employs 11 to 50 people.
Where is 7 Hills Pharma based?
7 Hills Pharma is headquartered in Houston, United States, in the North America region.
How does 7 Hills Pharma make money?
Two revenue lines are on record. Licensing and Partnership Revenue is the primary driver. The others are nondilutive Grant Funding.
Who are 7 Hills Pharma's main competitors?
Direct peers on record are Werewolf Therapeutics, Corvus Pharmaceuticals, Surface Oncology, Jounce Therapeutics, Apexigen, Compugen and Pyxis Oncology. Broad incumbents are Bristol-Myers Squibb and Merck & Co.. Adaptimmune Therapeutics is listed as an emerging player.
Does 7 Hills Pharma have an API?
No public API is recorded for 7 Hills Pharma.
What industry is 7 Hills Pharma in?
7 Hills Pharma's product category is Immuno-oncology biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies). Its NAICS code is 325412 and its SIC code is 2834.